{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-087227","form_type":"8-K","ticker":"OCUL","cik":"0001393434","company_name":"OCULAR THERAPEUTIX, INC","filed_at":"2022-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:55.593144+00:00","generated_at":"2026-06-24T02:41:27.764640+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Ocular Therapeutix Q2 net product rev $12.1M (+9% YoY); net loss $18.8M; FY guidance reaffirmed","bullets":["DEXTENZA net product revenue $12.1M in Q2 2022, up 9% YoY from $11.1M; total net revenue $12.3M.","Net loss $18.8M ($0.24 basic / $0.25 diluted EPS) vs $8.5M loss in Q2 2021.","Reiterates FY2022 DEXTENZA net product revenue guidance of $55-60M (26%-38% growth).","Cash and equivalents $134.5M at June 30, 2022; expects to fund operations through 2023.","Interim OTX-TKI (wet AMD) Phase 1 data to be presented at AAO in September 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-087227","json":"https://secwatch.observer/filing/0001104659-22-087227.json","markdown":"https://secwatch.observer/filing/0001104659-22-087227.md","text":"https://secwatch.observer/filing/0001104659-22-087227.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1393434/000110465922087227/0001104659-22-087227-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1393434/000110465922087227/tm2222774d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T02:41:27.764640+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}